StockWatch
·
Biotechnology: Pharmaceutical Preparations
Corporate ActionJun 2, 2026, 08:36 AM

SELLAS Receives $28.7M from Warrant Exercises; Cash $135.8M

AI Summary

SELLAS Life Sciences Group, Inc. announced an update on its financial position, reporting $107.1 million in cash and cash equivalents as of March 31, 2026. The company subsequently received approximately $28.7 million in proceeds from common stock warrant exercises during April and May 2026, bringing its total cash to $135.8 million. As of June 2, 2026, SELLAS had 196,632,574 shares of common stock outstanding.

Key Highlights

  • Cash and cash equivalents totaled $107.1 million as of March 31, 2026.
  • Received approximately $28.7 million in proceeds from common stock warrant exercises in April and May 2026.
  • Total cash and cash equivalents increased to $135.8 million.
  • 196,632,574 shares of common stock were outstanding as of June 2, 2026.